Displaying drugs 2876 - 2900 of 3936 in total
CSL324
CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques. It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.
Investigational
2-(5-fluoro-pentyl)-2-methyl-malonic-acid
2-(5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 for Early Detection of Response of Brain Metastases to SRS).
Investigational
Matched Description: … 5-fluoro-pentyl)-2-methyl-malonic-acid is under investigation in clinical trial NCT00696943 (18F ML-10 …
Briquilimab
Briquilimab is a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit).
Investigational
Revamilast
Revamilast has been used in trials studying the treatment of Asthma and Rheumatoid Arthritis.
Investigational
Matched Iupac: … 3,5-dichloro-4-[10-(difluoromethoxy)-8-oxa-4-azatricyclo[7.4.0.0^{2,7}]trideca-1(9),2,4,6,10,12-hexaene …
ARCT-810
ARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.
Investigational
Ty800
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
XL820
XL820 is investigated for use/treatment in solid tumors. XL820 is a solid. The proteins that XL820 inhibit include platelet-derived growth factor receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a variety of...
Investigational
GW-813893
Experimental
BI-836858
Investigational
PT886
PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)
Investigational
Lactobacillus brevis
Investigational
Tetrathiomolybdate
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is...
Investigational
Matched Salts cas: … 649749-10-0 …
V-SARS
COVID-19 convalescent plasma is currently being acquired from recovered COVID-19 patients and used as prophylaxis for the virus. This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. Immunitor Inc., the sponsor, is currently testing this oral...
Investigational
Matched Description: … [COVID-19 convalescent plasma] is currently being acquired from recovered COVID-19 patients and used …
CoVac-1
Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine candidate created from HLA class I and HLA-DR T-cell epitopes of the S-protein . It is being investigated in the clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults...
Investigational
Matched Description: … Sponsored by the University Hospital Tuebingen in Germany, CoVac-1 is a multi-peptide COVID-19 vaccine ... clinical trial NCT04546841 (Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 …
Esuberaprost
Investigational
Mdl 101,146
Experimental
V1003
V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior...
Investigational
OBE101
OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine. Obecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management...
Investigational
CAD106
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
BNC105
Investigational
IMM101
IMM-101 is a heat-inactivated immune-activating mycobacterial product. It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039]. Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help...
Investigational
Matched Description: … 1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 …
AIC100
Investigational
4A10
Investigational
Zk-806450
Experimental
ZK-806711
Experimental
Displaying drugs 2876 - 2900 of 3936 in total